GlassScriptPhysician profile
James A Bobenhouse
NPI 1760431100
$13,613.33
in general payments reported to CMS, 2019-2025
83 companies · $2,674 in 2025
The $2,674 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $1,266 · 2021: $1,967 · 2022: $2,202 · 2023: $2,033 · 2024: $2,114 · 2025: $2,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,753 · Education: $68.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,752.79 |
| Education | $68.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,117.40 | 2020-2025 | Qulipta, Ubrelvy, Duopa |
| Novartis Pharmaceuticals Corporation | $1,000.30 | 2019-2025 | |
| Ucb, INC. | $898.39 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Biogen, INC. | $843.32 | 2019-2025 | Vumerity, Spinraza, Qalsody |
| Csl Behring | $477.72 | 2019-2025 | Hizentra |
| Supernus Pharmaceuticals, INC. | $469.07 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $428.46 | 2019-2025 | Ultomiris |
| Eisai INC. | $409.87 | 2019-2025 | |
| Genzyme Corporation | $382.86 | 2019-2025 | |
| Lundbeck LLC | $368.28 | 2019-2025 | Rexulti, Vyepti |
| Amgen INC. | $364.67 | 2019-2025 | |
| Argenx US, INC. | $326.47 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $291.84 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $290.82 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $266.25 | 2021-2025 |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $257.96 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $252.88 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Acadia Pharmaceuticals INC | $245.50 | 2020-2025 | Nuplazid |
| Mallinckrodt Hospital Products INC. | $214.37 | 2020-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $206.64 | 2023-2025 | Hyqvia, Gammagard |
| Teva Pharmaceuticals USA, INC. | $195.25 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $194.75 | 2020-2022 | |
| Tanabe Pharma America, INC. | $189.39 | 2019-2025 | Radicava |
| Neurocrine Biosciences, INC. | $187.66 | 2019-2024 | Ingrezza |
| Mdd US Operations, LLC | $184.16 | 2020-2024 | Gocovri, Gocovri |
| Catalyst Pharmaceuticals, INC. | $168.31 | 2020-2024 | Fycompa |
| Ani Pharmaceuticals, INC. | $161.04 | 2023-2025 | Purified Cortrophin Gel |
| Neurelis, INC. | $154.81 | 2020-2022 | |
| Adamas Pharmaceuticals, INC. | $152.77 | 2019-2021 | |
| Kyowa Kirin, INC. | $142.47 | 2020-2023 | Nourianz |
| E.R. Squibb & Sons, L.L.C. | $142.03 | 2020-2022 | |
| Greenwich Biosciences, INC. | $136.83 | 2019 | |
| Vanda Pharmaceuticals INC. | $127.57 | 2024-2025 | Ponvory |
| Avanir Pharmaceuticals, INC. | $127.53 | 2019-2022 | |
| Pfizer INC. | $113.65 | 2024-2025 | |
| Genentech USA, INC. | $107.32 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $106.45 | 2020-2025 | Rytary, Crexont |
| Jazz Pharmaceuticals INC. | $103.92 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $102.67 | 2021-2025 | Onpattro |
| Banner Life Sciences, LLC | $91.95 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $80.95 | 2023-2025 | Nuedexta, Rexulti |
| Merz Pharmaceuticals, LLC | $78.18 | 2021-2025 | Xeomin, Inbrija |
| Octapharma USA, INC. | $73.91 | 2022-2025 | Octagam Immune Globulin (Human) |
| Arbor Pharmaceuticals, INC. | $69.33 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $68.72 | 2021 | |
| Almatica Pharma LLC | $65.56 | 2021-2023 | Gralise |
| Astrazeneca Pharmaceuticals LP | $58.89 | 2024-2025 | Wainua |
| Horizon Therapeutics Plc | $58.28 | 2021-2023 | Uplizna |
| Allergan, INC. | $58.03 | 2019-2022 | |
| Hospira, INC. | $55.11 | 2024-2025 | |
| Janssen Biotech, INC. | $55.04 | 2025 | |
| Axsome Therapeutics, INC. | $55.03 | 2023-2025 | Sunosi, Symbravo |
| Abbott Laboratories | $47.02 | 2022-2024 | Infinity |
| Ge Healthcare | $46.32 | 2020-2023 | |
| Grt US Holding, INC. | $44.86 | 2021-2022 | |
| Acorda Therapeutics, INC | $44.52 | 2019-2021 | |
| Chiesi USA, INC. | $41.78 | 2019-2020 | |
| Sarepta Therapeutics, INC. | $40.19 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $39.80 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $38.29 | 2022 | |
| Medtronic, INC. | $37.31 | 2021-2025 | Linq II |
| Azurity Pharmaceuticals, INC. | $32.15 | 2024 | Horizant |
| Cycle Pharmaceuticals INC | $31.15 | 2025 | Tascenso Odt |
| Ultragenyx Pharmaceutical INC. | $30.38 | 2022-2023 | |
| Itf Therapeutics LLC | $30.37 | 2025 | |
| Zogenix INC. | $27.67 | 2021 | |
| Boston Scientific Corporation | $26.97 | 2023 | Vercise |
| Averitas Pharma INC. | $25.63 | 2023 | Qutenza |
| Amicus Therapeutics, INC. | $21.41 | 2024 | Pombiliti, Opfolda |
| Baxter Healthcare | $19.84 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.70 | 2025 | Keveyis |
| Corium, LLC | $18.85 | 2022 | |
| Tg Therapeutics, INC. | $18.22 | 2024 | |
| Mirum Pharmaceuticals, INC. | $17.60 | 2024 | Cholbam |
| Genentech, INC. | $17.46 | 2020 | |
| Ns Pharma, INC. | $16.23 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $15.92 | 2023 | Relyvrio |
| Sumitomo Pharma America, INC. | $15.78 | 2023 | Aptiom |
| Portola Pharmaceuticals, LLC | $15.60 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.31 | 2020 | |
| Edw Pharma, INC. | $14.02 | 2020 | |
| Medtronic Vascular, INC. | $12.66 | 2019 | |
| Ceribell, INC. | $10.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bobenhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.